28538498|t|Ghrelin Protects the Thymic Epithelium From Conditioning-Regimen - Induced Damage and Promotes the Restoration of CD4+ T Cells in Mice After Bone Marrow Transplantation
28538498|a|The delay in immune reconstitution after hematopoietic stem cell transplantation (HSCT), especially a delay in central immune reconstitution, leads to opportunistic infections and disease relapse after transplantation and affects the long-term outcome of HSCT. This delay is mainly attributable to thymic damage after myeloablative chemotherapy and radiotherapy METHODS: We established a model of allogeneic bone marrow transplantation (BMT) in mice and administered ghrelin (GRL) 7 days before the conditioning regimen or the day after BMT. All the GRL - treated mice, especially those administered GRL prior to the conditioning regimen, exhibited more intact thymic architecture and a more rapid restoration of CD4 T lymphocytes after BMT than those of the corresponding control mice. Moreover, the levels of T cell receptor excision circles (TRECs) were significantly higher in the mice treated with GRL prior to the conditioning regimen than in the control mice at 28 days after BMT. Our finding s suggest that GRL may be a novel potential therapeutic approach to protecting the thymic epithelium from conditioning-regimen - induced damage and promoting rapid and durable thymic and peripheral CD4 T cell recovery after HSCT.
28538498	0	7	Ghrelin	T116,T125	C0911014
28538498	8	16	Protects	T033	C1545588
28538498	21	38	Thymic Epithelium	T025	C0229951
28538498	44	64	Conditioning-Regimen	T061	C0376450
28538498	67	74	Induced	T169	C0205263
28538498	75	81	Damage	T169	C1883709
28538498	86	94	Promotes	T052	C0033414
28538498	99	110	Restoration	T061	C1283255
28538498	114	126	CD4+ T Cells	T025	C0039215
28538498	130	134	Mice	T015	C0026809
28538498	141	168	Bone Marrow Transplantation	T061	C0005961
28538498	173	178	delay	T079	C0205421
28538498	182	203	immune reconstitution	T033	C1960768
28538498	210	249	hematopoietic stem cell transplantation	T061	C0472699
28538498	251	255	HSCT	T061	C0472699
28538498	271	276	delay	T079	C0205421
28538498	288	309	immune reconstitution	T047	C1096197
28538498	320	344	opportunistic infections	T047	C0029118
28538498	349	364	disease relapse	T047	C0277556
28538498	371	386	transplantation	T061	C0040732
28538498	403	412	long-term	T079	C0443252
28538498	413	420	outcome	T080	C0085415
28538498	424	428	HSCT	T061	C0472699
28538498	435	440	delay	T079	C0205421
28538498	467	480	thymic damage	T037	C3897359
28538498	487	513	myeloablative chemotherapy	T061	C1513784
28538498	518	530	radiotherapy	T061	C1522449
28538498	543	554	established	T080	C0443211
28538498	566	576	allogeneic	T080	C1515895
28538498	577	604	bone marrow transplantation	T061	C0005961
28538498	606	609	BMT	T061	C0005961
28538498	614	618	mice	T015	C0026809
28538498	623	635	administered	T169	C1521801
28538498	636	643	ghrelin	T116,T125	C0911014
28538498	645	648	GRL	T116,T125	C0911014
28538498	652	656	days	T079	C0439228
28538498	668	688	conditioning regimen	T061	C0376450
28538498	706	709	BMT	T061	C0005961
28538498	719	722	GRL	T116,T125	C0911014
28538498	725	732	treated	T169	C1522326
28538498	733	737	mice	T015	C0026809
28538498	756	768	administered	T169	C1521801
28538498	769	772	GRL	T116,T125	C0911014
28538498	786	806	conditioning regimen	T061	C0376450
28538498	830	836	thymic	T023	C0040113
28538498	861	866	rapid	T080	C0456962
28538498	867	878	restoration	T061	C1283255
28538498	882	899	CD4 T lymphocytes	T025	C0039215
28538498	906	909	BMT	T061	C0005961
28538498	942	949	control	T080	C0243148
28538498	950	954	mice	T015	C0026809
28538498	980	1012	T cell receptor excision circles	T114	C1515131
28538498	1014	1019	TRECs	T114	C1515131
28538498	1026	1046	significantly higher	T081	C4055637
28538498	1054	1058	mice	T015	C0026809
28538498	1059	1071	treated with	T061	C0332293
28538498	1072	1075	GRL	T116,T125	C0911014
28538498	1089	1109	conditioning regimen	T061	C0376450
28538498	1122	1129	control	T080	C0243148
28538498	1130	1134	mice	T015	C0026809
28538498	1141	1145	days	T079	C0439228
28538498	1152	1155	BMT	T061	C0005961
28538498	1161	1168	finding	T033	C0243095
28538498	1184	1187	GRL	T116,T125	C0911014
28538498	1197	1202	novel	T080	C0205314
28538498	1203	1212	potential	T080	C3245505
28538498	1213	1224	therapeutic	T169	C0302350
28538498	1252	1258	thymic	T023	C0040113
28538498	1259	1269	epithelium	T024	C0014609
28538498	1275	1295	conditioning-regimen	T061	C0376450
28538498	1298	1305	induced	T169	C0205263
28538498	1306	1312	damage	T169	C1883709
28538498	1327	1332	rapid	T080	C0456962
28538498	1345	1351	thymic	T023	C0040113
28538498	1356	1366	peripheral	T082	C0205100
28538498	1367	1377	CD4 T cell	T025	C0039215
28538498	1378	1386	recovery	T040	C2004454
28538498	1393	1397	HSCT	T061	C0472699